Biocryst Pharmaceuticals (BCRX) Common Equity (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Common Equity came in at -$553.8 million in Q1 2026, down 22.55% YoY from -$715.1 million in Q1 2025, and down 364.82% on a QoQ basis from -$119.2 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Common Equity (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Common Equity data on file, last reported at -$553.8 million in Q1 2026.
- Quarterly Common Equity fell 22.55% year-over-year to -$553.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$553.8 million (down 22.55% YoY) and the FY2025 annual result came in at -$119.2 million, up 74.96% from the prior year.
- Common Equity slipped to -$553.8 million in Q1 2026, from -$119.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$119.2 million in Q4 2025 to a low of -$553.8 million in Q1 2026.
- A 5-year average of -$372.3 million and a median of -$411.0 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity tumbled 175.36% — and 2025, when it surged 74.96%.
- Tracing BCRX's Common Equity over 5 years: stood at -$294.6 million in 2022, then tumbled by 54.63% to -$455.5 million in 2023, then dropped by 4.48% to -$475.9 million in 2024, then surged by 74.96% to -$119.2 million in 2025, then tumbled by 364.82% to -$553.8 million in 2026.
- The last three Common Equity figures came in at -$553.8 million (Q1 2026), -$119.2 million (Q4 2025), and -$387.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | -454.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -454.29 Mn |
| Mar 31, 2026 | -553.84 Mn |
| Dec 31, 2025 | -119.15 Mn |
| Sep 30, 2025 | -387.89 Mn |
| Jun 30, 2025 | -421.59 Mn |
| Mar 31, 2025 | -451.93 Mn |
| Dec 31, 2024 | -475.93 Mn |
| Sep 30, 2024 | -468.56 Mn |
| Jun 30, 2024 | -475.61 Mn |
| Mar 31, 2024 | -476.17 Mn |
| Dec 31, 2023 | -455.53 Mn |
| Sep 30, 2023 | -410.99 Mn |
| Jun 30, 2023 | -388.71 Mn |
| Mar 31, 2023 | -328.29 Mn |
| Dec 31, 2022 | -294.60 Mn |
| Sep 30, 2022 | -242.66 Mn |
| Jun 30, 2022 | -213.23 Mn |
| Mar 31, 2022 | -164.22 Mn |
| Dec 31, 2021 | -106.99 Mn |
| Sep 30, 2021 | -147.04 Mn |